Floatz logo

Bms-833923

Smoothened

Bristol-Myers SquibbSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Smoothened cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Bms-833923 is also rated in:

neoplasmDormant
CC
Indicative ·
47 / 100
View asset →
Hedgehog PathwayDormant
CC
Indicative ·
47 / 100
View asset →
skin basal cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →